ALX Oncology’s evorpacept shows potential in Phase II gastric cancer trial
The study's findings showed a clinically meaningful improvement in ORR and mDOR among the participants.
01 August 2024
01 August 2024
The study's findings showed a clinically meaningful improvement in ORR and mDOR among the participants.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.